GABA-A modulation comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-08-25. Numbers and descriptions here follow the published literature rather than marketing material.
Development work on the compound began in the 1980s and 1990s at the Institute of Molecular Genetics in Moscow, within the same research programme that produced the peptide Semax. Early investigators sought a tuftsin derivative with improved resistance to enzymatic breakdown and with activity in the central nervous system after peripheral administration. Most of the primary literature from this period was published in Russian, a factor that still shapes how easily the findings can be checked by outside groups.
Naming for this compound is not fully standardised in English sources. The spelling Selanc appears in some transliterations, and catalogue entries may instead list the peptide sequence itself as the identifier. Reference material sometimes groups it with other short synthetic peptides studied for behavioural effects, which can create confusion when citations are compared. Distinguishing the exact sequence from related tuftsin analogues is therefore a practical first step when reviewing any dataset or specification sheet.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro, frequently abbreviated as TKPRPGP. It was designed as a structural analogue of tuftsin, a naturally occurring tetrapeptide released by enzymatic cleavage of the immunoglobulin heavy chain. The two additional proline residues at the C-terminal end extend the parent chain and change how the molecule behaves in solution. The free peptide has a calculated molecular mass of approximately 751.9 g/mol and is generally supplied as a lyophilised white to off-white powder.
Regulatory status differs sharply by region. Selank holds a Russian marketing authorization, where it is supplied mainly as nasal drops, while authorities elsewhere have not approved it for medical use. Material sold internationally is therefore usually labeled as a research chemical rather than a medicine. Peer-reviewed publications come predominantly from Russian laboratories, and sample sizes are generally small. Whether the compound produces comparable effects under independent, well-controlled replication remains an open question that the broader literature has not settled.
Selank is a synthetic heptapeptide developed in Russia as a structural analogue of tuftsin, a naturally occurring immunomodulatory tetrapeptide. Its sequence, Thr-Lys-Pro-Arg-Pro-Gly-Pro, keeps the tuftsin core at the N-terminus and appends a Pro-Gly-Pro tail. Researchers at the Institute of Molecular Genetics in Moscow synthesized the compound during the 1990s while searching for peptides with combined anxiolytic and immunomodulatory activity. The added tail was intended to resist enzymatic cleavage and prolong the molecule's presence in circulation.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | Tuftsin analogue |
| Sequence | Thr-Lys-Pro-Arg-Pro-Gly-Pro | Single-letter form: TKPRPGP |
| Molecular formula | C33H57N11O9 | Calculated for the free peptide |
| Molecular weight | About 751.9 g/mol | Derived from the sequence |
| Appearance | White to off-white powder | Typical lyophilised form |
Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.
Enzymatic stability motivates the extra three residues at the carboxyl end. Native tuftsin is cleaved quickly by circulating aminopeptidases and carboxypeptidases, which limits its duration of action and its usefulness as a tool compound. Extending the chain with proline-rich segments is a common design tactic because proline constrains the backbone and slows proteolysis. The same Pro-Gly-Pro motif appears in other Russian-developed peptides of the era. Whether the full seven-residue chain is required for activity, or whether it acts mainly as a prodrug releasing tuftsin, remains unresolved.
Published work on this peptide almost always uses intranasal delivery, with drops or a spray applied to the nasal mucosa. Some animal experiments have used subcutaneous or intraperitoneal injection, and a smaller number have compared routes directly. Oral administration is not a focus of the literature, because short peptides of this size are broken down by digestive enzymes and cross intestinal barriers poorly. How much of an intranasal dose reaches the bloodstream intact in humans remains an open question.
Animal studies have examined behaviour in tests of anxiety, memory retention and stress response, and several report changes in neurotrophic or neurotransmitter-related markers. The human evidence base is much smaller, consisting mainly of short trials conducted in Russia with limited reporting in English-language journals. Sample sizes are modest and outcome measures vary between studies, so the findings are best described as preliminary. Independent replication under modern trial standards has not been widely reported.
Laboratory work relies on standard behavioral paradigms. Rodents are tested in the elevated plus maze, open field, and passive avoidance tasks, with outcomes compared against diazepam or vehicle controls. Intranasal dosing is used most often because it bypasses first-pass metabolism, though intraperitoneal and intravenous routes also appear in published protocols. Biochemical endpoints include tissue BDNF concentrations, cytokine levels, and monoamine metabolites. Human data are limited to small Russian trials reporting reduced anxiety scores; most were not prospectively registered, and few employed independent outcome assessment.
Measuring peptide exposure inside the brain is technically difficult. Selank is degraded rapidly in plasma, and assays must separate intact peptide from fragments, which favors targeted mass spectrometry over immunoassays alone. Reported half-lives are short, on the order of minutes, so effects observed hours later are attributed to downstream signaling rather than to the parent compound. Blood-brain barrier permeability is debated and rarely quantified directly. Gaps include absent dose-response characterization, inconsistent reporting of purity, and almost no pharmacokinetic data from human participants.
Selank is studied chiefly as an animal-model anxiolytic with proposed secondary effects on memory and immune signaling. Reported mechanisms include modulation of the GABA-A receptor complex, inhibition of enkephalin-degrading enzymes, and shifts in monoamine turnover within limbic structures. Some experiments describe increased expression of brain-derived neurotrophic factor in the hippocampus after repeated dosing. No single molecular target has been confirmed, and the peptide does not bind any receptor with the selectivity typical of a conventional small-molecule drug. Mechanism therefore remains a set of hypotheses rather than an established pathway.
Proposed mechanisms centre on the GABAergic system. Animal and tissue studies report changes in GABA-A receptor expression and reduced activity of GABA transaminase, the enzyme that degrades GABA. Effects on monoamine turnover, including serotonin and dopamine pathways, are also described, and a separate line of work links the peptide to increased expression of brain-derived neurotrophic factor in hippocampal tissue. Most of these findings come from rodent models and cell preparations. How the individual observations combine into a single coherent mode of action is not settled.
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Consumption of breakfast cereal is under preliminary research for the potential to improve nutrition and affect chronic diseases. Regular breakfast cereal consumption is associated with less risk of being overweight or obese and high-fiber breakfast cereals are associated with a lower risk of diabetes. Fortified breakfast cereals with iron can be an effective option to reduce risk of anemia in children.
== Civilization implications == There are many historical examples of human civilization undergoing large-scale transitions, such as the Industrial Revolution. The transitions between Kardashev scale levels could potentially represent similarly dramatic periods of social upheaval, as they involve exceeding the hard limits of the resources available within a civilization's existing territory. A common speculation is that the transition from Type 0 to Type I could carry a strong risk of self-destruction, since in some scenarios there would be no room for further expansion on the civilization's home planet, as in a Malthusian catastrophe. For example, excessive energy consumption without adequate heat removal could plausibly render the planet of a Type I approaching civilization unsuitable for the biology of the dominant life forms and their food sources. Using Earth as an example, ocean temperatures above 95 °F (35 °C) would endanger marine life and make it difficult, if not impossible, for mammals to cool to temperatures suitable for their metabolism. Of course, these theoretical speculations may not become problems, possibly through the application of future engineering and technology. Also, by the time a civilization reaches Type I, it may have colonized other planets or established O'Neill-type colonies, so that waste heat could be distributed throughout the star system.
=== Nationalist Congress Party === Vaghela joined the Nationalist Congress Party (NCP) in January 2019. He was appointed the National General Secretary as well as the State President of the party. He was removed from the post of State President in early June 2020, a week before 2020 Indian Rajya Sabha elections. He resigned from the NCP on 22 June 2020 citing his displeasure at his removal from the post and cross voting by NCP's only MLA Kandhal Jadeja in Rajya Sabha election.
== Synthetic ligands == The non-peptide NPS receptor antagonist SHA-68 blocks the effects of NPS in animals and is anxiogenic. Several peptide derived NPS agonists and antagonists have also been developed.
A number of studies have shown that tobacco use is a significant factor in miscarriages among pregnant smokers, and that it contributes to a number of other threats to the health of the fetus such as low birth weight and pre-term birth. It slightly increases the risk of neural tube defects. Environmental tobacco smoke exposure and maternal smoking during pregnancy have been shown to cause lower infant birth weights.
Sources: en.wikipedia.org
=== 18 March === President Putin visited Crimea on the ninth anniversary of the peninsula's annexation. The Black Sea Grain Initiative between Ukraine and Russia, which was due to expire on 18 March, was extended.
=== Post–surgical recovery === Convalescence The rhinoplasty patient returns home after surgery, to rest, and allow the nasal cartilage and bone tissues to heal the effects of having been forcefully cut. Assisted with prescribed medications—antibiotics, analgesics, steroids—to alleviate pain and aid wound healing, the patient convalesces for about 1-week, and can go outdoors. Post-operatively, external sutures are removed at 4–5 days; the external cast is removed at 1-week; the stents are removed within 4–14 days; and the "panda eyes" periorbital bruising heal at 2-weeks. If an alar base reduction is performed conjunctively within the Rhinoplasty, these sutures need to be removed within 7–10 days post operatively. Throughout the first year post-operative, in the course of the rhinoplastic wounds healing, the tissues will shift moderately as they settle into being a new nose. Furthermore, as rhinoplasty climbs the ladder of surgical procedures performed to achieve an aspired appearance, especially amongst women, the relationship between body image and mental state must be examined in order to destigmatize motives behind the surgical intervention.
=== Range === DASH7 provides a link budget of up to 140 dB with 27 dBm transmission power, which positions the technology as medium-range, compared to short-range (Bluetooth, Wi-Fi, ...) and long-range (LoRaWAN, SigFox). Note that higher ranges are always obtained at the expense of per-bit power consumption and transmission duration. Low-power long-range technologies are generally not truly bi-directional, as the regular scanning duty is pretty high. In this context, DASH7 is a very good compromise between range, power consumption, and bi-directionality and is very suitable for industrial applications with effective range of 100 to 500 m. In line-of-sight situations, DASH7 devices today advertise read ranges of 1 kilometer or more, however, ranges of up to 10 km have been tested by Savi Technology and are easily achievable in the European Union, where governmental regulations are less constrained than in the USA.
A follow-up analysis, and a letter to the editor by Gregory Francis from the Department of Psychological Sciences, Purdue University, demonstrated that the problem in the paper could be a simple reporting error in which t-statistics were reported as F-statistics by mistake. Francis also showed that this error does not negate the findings in the original article. In November 2022, the Israeli TV investigative show Hamakor (Channel 13), aired an episode questioning a number of Ariely's studies that were not reproducible or whose reliability was dubious in terms of the way they were carried out, the data collected, or whether the studies were carried out at all. For example, Ariely claimed that data for his "Ten Commandments" study were collected in 2004–2005 at UCLA with the assistance of Aimee Drolet Rossi. However, despite being thanked in the 2004 paper for collecting the data almost 20 years later, Rossi denies having run the study, and UCLA has issued a statement that the study did not take place there. Ariely told The New Yorker that the surveys were collected at UCLA but processed by an assistant at MIT, a mixup that he credited for the confusion surrounding Rossi and UCLA's role in the study. An analysis conducted by the American Marketing Association on the study in question found that the study's results were largely replicable using the data provided by the authors, although conditions had been dropped from the first two experiments in the study.
Sources: en.wikipedia.org
However, some studies have also shown that malolactic fermentation may diminish primary fruit aromas such as Pinot noir, often losing raspberry and strawberry notes after MLF. Additionally, red wines may endure a loss of color after MLF due to pH changes that causes a shift in the equilibrium of the anthocyanins which contribute to the stability of color in wine.
== Overview == Platelet-mimicking particles, an innovation of drug delivery since the mid-twentieth century, are designed to mimic the functionality of natural platelets, with ongoing research focusing on optimizing their biocompatibility, clot integration, and targeted delivery capabilities. Advances in nanotechnology and molecular engineering have enabled the development of platelet-mimicking drug delivery systems. Current research aims to replicate key platelet functions such as adhesion, aggregation, and clotting to enhance hemostatic responses and targeted therapies. Primary synthetic platelet preparations involve nanoscale polymeric architectures, peptides, or extracellular vesicles to improve biocompatibility and therapeutic efficacy. Current iterations of synthetic platelets - hydrogel-based nanoparticles that mimic the size, mechanics, and shape of natural platelets - have demonstrated efficacy in promoting clotting and wound healing in preclinical studies involving rodents and pigs. Originally designed to improve patient outcomes related to hemostasis, synthetic platelets are now being explored in other therapeutic areas including immune modulation and anticancer treatment. For example, a recent platelet design engineered for anticancer treatment can be freeze-dried and rehydrated when needed, offering a longer shelf life compared to natural platelets, which typically degrade rapidly when stored.
== Contraindications == Lurasidone is contraindicated in individuals who are taking strong inhibitors of the liver enzyme CYP3A4 (ketoconazole, clarithromycin, ritonavir, levodropropizine, etc.) or inducers (carbamazepine, St. John's wort, phenytoin, rifampicin etc.). The use of lurasidone in pregnant women has not been studied and is not recommended; in animal studies, no risks have been found. Excretion in breast milk is also unknown; lurasidone is not recommended for breastfeeding women. The enzyme CYP3A4 is involved in the digestion of drugs. Inhibitors such as grapefruit juice block its function, resulting in too much drug in the body.
Sources: en.wikipedia.org
The sequence is Thr-Lys-Pro-Arg-Pro-Gly-Pro, commonly written as TKPRPGP. It shares the first four residues with tuftsin and carries three prolines in the chain. The proline-rich tail is the main structural feature that separates it from the parent tetrapeptide.
Selank is a synthetic analogue built on the tuftsin tetrapeptide Thr-Lys-Pro-Arg. Extra proline residues were added to the C-terminus during design work. That modification is intended to make the peptide less vulnerable to rapid enzymatic degradation.
Transliteration from Russian produces variant spellings such as Selanc. Many suppliers avoid the trade-style name entirely and list the peptide sequence. Comparing sequences rather than names is the reliable way to confirm two entries describe the same molecule.
Selank is a synthetic seven-amino-acid peptide modeled on tuftsin, a fragment of the immunoglobulin G heavy chain. It was designed in Russia to combine anxiolytic and immunomodulatory properties in one molecule.